Shares of BioSig Technologies Inc (NASDAQ:BSGM) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus target price of $11.88 for the company, according to Zacks. Zacks has also assigned BioSig Technologies an industry rank of 70 out of 255 based on the ratings given to its competitors.
Get BioSig Technologies alerts:Several analysts have issued reports on BSGM shares. Laidlaw set a $11.00 price objective on shares of BioSig Technologies and gave the company a “buy” rating in a research report on Wednesday, February 20th. Roth Capital began coverage on shares of BioSig Technologies in a research report on Thursday, December 6th. They set a “buy” rating and a $14.00 price target for the company. Finally, Zacks Investment Research downgraded shares of BioSig Technologies from a “buy” rating to a “hold” rating in a research report on Monday, November 19th.
NASDAQ:BSGM traded up $0.04 during trading hours on Tuesday, hitting $5.55. The stock had a trading volume of 15,928 shares, compared to its average volume of 52,062. BioSig Technologies has a 1-year low of $3.38 and a 1-year high of $7.88.
In related news, CEO Kenneth L. Londoner bought 8,500 shares of the business’s stock in a transaction on Thursday, January 10th. The shares were bought at an average cost of $4.38 per share, for a total transaction of $37,230.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kenneth L. Londoner bought 18,700 shares of the business’s stock in a transaction on Tuesday, January 22nd. The stock was bought at an average price of $4.35 per share, for a total transaction of $81,345.00. The disclosure for this purchase can be found here. 26.70% of the stock is currently owned by company insiders.
A hedge fund recently bought a new stake in BioSig Technologies stock. Millennium Management LLC bought a new position in shares of BioSig Technologies Inc (NASDAQ:BSGM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 156,822 shares of the company’s stock, valued at approximately $670,000. Millennium Management LLC owned 0.94% of BioSig Technologies as of its most recent SEC filing. 2.15% of the stock is owned by institutional investors.
About BioSig Technologies
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Read More: How Important is Technical Analysis of Stocks
Get a free copy of the Zacks research report on BioSig Technologies (BSGM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment